Introduction
============

Blunt chest-wall trauma accounted for over 15% of all trauma admissions to Emergency departments (EDs) worldwide \[[@B1]\]. Reported mortality ranges between 4 and 60%, however, no current national guidelines exist to assist in the management of this patient group unless the patient has severe, immediate life-threatening injuries \[[@B2]\]. The difficulties in the management of the blunt chest-wall trauma patient are becoming increasingly well recognised in the literature \[[@B3],[@B4]\]. The blunt chest-wall trauma patient commonly presents to the ED initially with no respiratory difficulties, but can develop respiratory complications approximately 48 to 72 hours later \[[@B5],[@B6]\]. Clinical symptoms are not considered an accurate predictor of outcome following non-life threatening blunt chest-wall trauma \[[@B7]\]. Decisions on the appropriate level of care required by the patient following discharge from the ED are therefore difficult, which is further compounded by the lack of current national guidelines. A number of well-documented risk factors for morbidity and mortality exist for blunt chest-wall trauma, including patient age, pre-existing disease, number of ribs fractured and the onset of pneumonia during the recovery phase \[[@B2],[@B8]\].

A prognostic model enables the clinician to use combinations of predictor values to estimate a probability that a specified outcome will occur \[[@B9]\]. The resulting model may be used to divide the patient into categories of risk or predict probabilities of a pre-specified outcome \[[@B9]\]. A number of models exist for blunt chest trauma, however, most are designed for use with patients with multiple injuries and very few have been externally validated or presented in a clinically practical way \[[@B3]\]. For the purpose of this study, blunt chest-wall trauma was defined as blunt chest injury resulting in chest wall contusion or rib fractures, with or without non-immediate life-threatening lung injury \[[@B2]\]. We have developed and validated a prognostic model for the development of complications following blunt chest-wall trauma. Using the results of the prognostic model, we have also developed a simple risk score for use in the clinical setting which can assist the clinician in the management of the blunt chest-wall trauma patient.

Materials and methods
=====================

There were two distinct phases to the overall study; the development and the validation phases. Published guidelines for prognostic model development were followed throughout the completion of this work \[[@B9]-[@B12]\]. These guidelines outlined the stages of model development and the appropriate statistical analysis that should be undertaken at each phase \[[@B9]-[@B12]\].

Development phase study design
------------------------------

Data were collected retrospectively from the medical notes of each patient. If there was no record in the patient's notes of chronic lung disease, cardiovascular disease, use of pre-injury anticoagulants or current smoking status, then it was assumed that these predictors were absent. The number of rib fractures was determined from the chest radiograph if not documented in the medical notes.

Patients
--------

The prognostic model was developed on a sample of 276 patients who presented to the ED of a large regional trauma centre in South Wales between 2009 and 2011, with a primary diagnosis of blunt chest-wall trauma. Patients were excluded if they were under 18 years of age or if they had sustained any immediate life-threatening injury. As eight prognostic variables were under investigation, a total of 80 blunt chest-wall trauma patients who developed complications were needed in the analysis \[[@B13]\].

Outcomes
--------

The development of complications following blunt chest-wall trauma was the composite outcome measure investigated in this study. Data collection for this outcome was completed from the time the patient presented to the ED through to discharge from hospital. Patients were reported to have developed complications if one or more of the following were documented in their medical records; in-hospital mortality, morbidity including all pulmonary complications (chest infection, pneumonia, haemothorax, pneumothorax, pleural effusion, or empyema), ICU admission, or a prolonged length of stay as defined as a total hospital stay of seven or more days \[[@B14],[@B15]\].

Prognostic variables
--------------------

For the development of the prognostic model, we considered age, number of rib fractures, chronic lung disease, cardiovascular disease, use of pre-injury anti-coagulants, smoking status and oxygen saturations and respiratory rate on initial assessment in the ED. These risk factors were based on previous research \[[@B2],[@B8],[@B16]\].

Analysis
--------

Baseline characteristics were presented as median and interquartile range (due to non-normal distributions) for the continuous variables and numbers and percentages for categorical variables. Differences between the baseline characteristics in the development and validation samples were analysed using the Mann-Whitney *U*-test (continuous variables) and Fisher's exact test (categorical variable). Odds ratios and 95% CI were presented from the univariable analysis. All significant prognostic variables at 5% significance on the univariable analysis were included in final analysis. Multivariable logistic regression analysis using fractional polynomials (to assess linearity of the continuous variables) identified five significant predictors using the Akaike information criterion with a backward elimination approach. We quantified the predictive contribution of each variable by its *z*-score (the regression coefficient divided by its standard error). There was less than 2% missing data, therefore we used a simple imputation method to avoid exclusion of patients from the final analysis \[[@B17]\].

Performance of the model
------------------------

The final prognostic model was based on five prognostic variables which were significant at the *P* \<0.05 level following multivariable logistic regression analysis. We assessed model performance using analysis of calibration and discrimination. Calibration was assessed graphically and with the Hosmer-Lemeshow test. Discrimination was assessed with the *c*-statistic (equivalent to the area under the receiver operator curve) \[[@B17]\].

Validation phase study design
-----------------------------

A multi-centre prospective study design was used in order to externally validate the model, in which seven hospitals in England and Wales between 2012 and 2013 participated in data collection. A total of 237 patients was included, which was a sufficient sample size for a validation study \[[@B18]\]. The model was validated by comparing predicted versus observed outcomes and performance assessed using calibration and discrimination analysis. As a result of the lower calibration in the validation model, the final model was updated through the application of a correction factor to adjust the slope intercept of the original model. This technique is outlined in the guidelines by Janssen *et al*. \[[@B19]\]. Sensitivity, specificity, positive and negative predictive values were calculated for the final model.

Score development
-----------------

We developed a simple clinical score based on the regression coefficients from the final model. To calculate the risk score for the individual predictors, the coefficient of each predictor was multiplied by a factor so that the smallest coefficient was transformed into a value close to one. This method was adapted from previous studies \[[@B20],[@B21]\]. These individual scores were then added together to provide an overall risk score for each patient. Using the validation sample, each patient's final overall risk score was compared to their probability of developing complications initially calculated using the final logistic regression equation. The individual final risk scores were categorised into groups (0 to 10, 11 to 15, 16 to 20, 21 to 25, 26 to 30 and ≥30) and the mean and standard deviation of all the corresponding probabilities were calculated. This would provide the clinician with a probability of the development of complications for each possible final risk score. Estimates of appropriate cut off points were included guiding the clinician as to whether the patient could be safely discharged home, or whether they should be admitted to a ward or intensive care unit.

Ethical approval
----------------

Full ethical approval for this study was granted by the South West Wales Research Ethics Committee. Written consent to participate and publish study findings was provided by each recruited patient.

Results
=======

General characteristics
-----------------------

Table [1](#T1){ref-type="table"} illustrates the baseline characteristics of the patients comparing the development and validation samples. Significant differences were recorded in rate of outcome and most predictors between the two groups. More of the patients were male (64%) and the most common injury mechanisms were fall (72%), road traffic accident (14%), sporting injury (9%) and assault (3%). A total of 31 (6%) deaths was recorded in both samples.

###### 

Comparison between baseline characteristics of patients in the development and validation samples

                                   **Development sample total**   **No complications**   **Complications**   **Validation sample total**   **No complications**   **Complications**   ***P*-value**
  ------------------------------- ------------------------------ ---------------------- ------------------- ----------------------------- ---------------------- ------------------- ---------------
                                               274                     113 (41%)             161 (59%)                   237                    161 (57%)             103 (43%)         \<0001\*
  **Age**                                    69 (28)                    62 (30)               76 (21)                  57 (34)                   47 (31)               71 (29)          \<0001\*
  **Number of rib fractures**                 3 (3)                      2 (3)                 3 (1)                    1 (3)                     0 (1)                 3 (3)           \<0.001\*
  **Oxygen saturations**                      95 (5)                     96 (4)               94 (6)                   97 (5)                     98 (2)               95 (7)           \<0.001\*
  **Respiratory rate**                        18 (6)                    18 (4.5)             20 (6.5)                  18 (6)                     16 (2)               20 (6)             0.062
  **Chronic lung disease**                  154 (56%)                   38 (34%)             116 (72%)                49 (21%)                   13 (8%)              36 (35%)          \<0.001\*
  **Cardiovascular disease**                116 (42%)                   34 (30%)             82 (51%)                 53 (22%)                   13 (8%)              40 (39%)          \<0.001\*
  **Smoker**                                 92 (34%)                   43 (38%)             49 (30%)                 67 (28%)                   40 (25%)             27 (26%)            0.213
  **Pre-injury anticoagulants**             117 (43%)                   28 (25%)             89 (55%)                 47 (20%)                    6 (4%)              41 (40%)          \<0.001\*

Number (percentages), median (interquartile range). \*Significant difference (*P*-value) between totals in development and validation samples.

Development phase univariable analysis
--------------------------------------

Results of the univariable analysis (in the development sample only) highlighted a number of significant predictors for the development of complications. Unadjusted odds ratios and the 95% CI are included for each of the categorical variables.

Development phase multivariable analysis
----------------------------------------

All eight predictors from Table [2](#T2){ref-type="table"} were included in the analysis (from the development sample only). Five significant predictors were included in the final model: age, number of rib fractures, chronic lung disease, use of pre-injury anticoagulants and oxygen saturations (Table [3](#T3){ref-type="table"}). Continuous variables were analysed as linear terms as there was no indication of non-linearity when analysed using the multivariable fractional polynomials. The number of rib fractures and chronic lung disease were the strongest predictors of the development of complications following blunt chest-wall trauma.

###### 

Univariable analysis: unadjusted odds ratios for the predictors of the development of complications

                               **No complications n = 113**   **Complications n = 161**   ***P*-value**   **Unadjusted odds ratios (95%CI)**
  --------------------------- ------------------------------ --------------------------- --------------- ------------------------------------
  Age                                     47 31                       71 (30.0)             0.0001\*                       
  Number of rib fractures                0 (1.0)                       3 (1.0)              0.0001\*                       
  Oxygen saturations                     98 (2.0)                     95 (7.0)              0.0001\*                       
  Respiratory rate                       18 (6.0)                     20 (8.0)               0.0794                        
  Chronic lung disease                   38 (34%)                     116 (72%)             0.0001\*                5.1 (3.0, 8.6)
  Pre-injury anticoagulants              28 (25%)                     89 (55%)              0.0001\*                3.8 (2.2, 6.4)
  Cardiovascular disease                 34 (30%)                     82 (51%)              0.0008\*                2.4 (1.5, 4.0)
  Smoking status                         43 (38%)                     49 (30%)               0.1964                 0.7 (0.4, 1.2)

Number and percentages, median (interquartile). \*Significant difference (*P*-value).

###### 

Multivariable predictive model

  **Predictor**                 **Odds ratio (95%CI)**   ***z*-score**
  ---------------------------- ------------------------ ---------------
  Age^a^                            1.0 (1.0, 1.0)           1.80
  Number of rib fractures^b^        1.5 (1.3, 1.9)           4.21
  Chronic lung disease              2.2 (1.2, 4.1)           2.50
  Pre-injury anticoagulants         1.9 (1.0, 3.7)           1.91
  Oxygen saturations^c^             0.9 (0.9, 1.0)           −1.55

^a^Per one year increase; ^b^per one fracture increase; ^c^per 1% decrease of oxygen saturations.

Performance of model
--------------------

The model showed excellent discrimination with a *c*-statistic of 0.80 (95% CI 0.75, 0.85). The model calibration is illustrated in the observed versus predicted outcomes graph in Figure [1](#F1){ref-type="fig"}. The model showed good calibration when evaluated with the Hosmer Lemeshow test (9.22, *P* = 0.32).

![**Calibration of model using expected and observed probabilities of development of complications.** Triangles show risk of outcome in tenths of patients with similar predicted probabilities. Dotted line: relationship between observed frequency and predicted probability of development of complications; broken line: ideal relationship between observed and predicted frequency of outcome in model with perfect calibration.](cc13873-1){#F1}

External validation
-------------------

In the validation phase of the study, the model was prospectively externally validated in seven hospitals in England and Wales. Discrimination of the final validation model was excellent with a *c*-index of 0.96 (95% CI 0.93, 0.98), although an increase in the *c*-statistic is unusual in a validation study. As expected, calibration was poorer in the validation model (Figure [2](#F2){ref-type="fig"}), therefore, we updated the model. The slope intercept of the development model was adjusted using a correction factor to correspond with the lower complication rate in the validation sample, which gave an improved discrimination and calibration (Figure [2](#F2){ref-type="fig"}). The results demonstrated that final model sensitivity was 80%, specificity was 96%, positive predictive value was 93% and negative predictive value was 86%.

![**External validation model calibration using observed versus predicted outcomes.** Red diamonds show risk of outcome in tenths of patients with similar predicted probabilities with intercept value of 3.72. Green triangles show risk of outcome in tenths of patients with similar predicted probabilities with updated intercept value of 3.97. Black broken line: ideal relationship between observed and predicted frequency of outcome in model with perfect calibration; red broken line: relationship between observed frequency and predicted probability of development of complications in original validation model; green line: relationship between observed frequency and predicted probability of development of complications in updated validation model.](cc13873-2){#F2}

Clinical score
--------------

Based on the results of the logistic regression analysis, we developed a simplified clinical score by transforming the regression coefficient of each predictor into an equivalent accurately weighted risk integer score (Table [4](#T4){ref-type="table"}). For example, a 67-year-old (score 6) patient with three rib fractures (score 9), a history of chronic lung disease (score 5) and oxygen saturations of 87% (score 4) would have a final risk score of 24 points.

###### 

Risk factor scores as transformed from the regression coefficients

                                  **Regression coefficient**   **Risk score**
  ------------------------------ ---------------------------- ----------------
  Age                                       0.0162                  1^a^
  Number of rib fractures                   0.418                   3^b^
  Chronic lung disease                      0.789                    5
  Pre-injury anticoagulant use              0.637                    4
  Oxygen saturation levels                 −0.0651                  2^c^

^a^Per additional 10-year increase starting at 10 years of age; ^b^per additional rib fracture; ^c^per 5% decrease in oxygen saturations starting at 94%.

Table [5](#T5){ref-type="table"} illustrates the final risk scores and their corresponding probability of developing complications following blunt chest-wall trauma. Using these results, for example, it is possible to estimate that a patient who scores 12 has a 29% (±8) probability of developing complications compared to a patient with a final risk score of 36 who has an 88% (±7) probability of developing complications.

###### 

Final risk scores and corresponding probability of developing complications

  **Final risk score**    **Probability mean ± SD**
  ---------------------- ---------------------------
  0 to 10                          13% ± 6
  11 to 15                         29% ± 8
  16 to 20                         52% ± 8
  21 to 25                         70% ± 6
  26 to 30                         80% ± 6
  31+                              88% ± 7

A final total risk score of ≥11 was the most accurate cut off point (in terms of sensitivity, specificity and predictive values) at which the blunt chest-wall trauma patient was considered at risk of developing complications. The percentage of patients who would have been correctly managed (admitted to hospital and subsequently developed complications) was 90% and those correctly discharged directly from the ED (who had not developed complications) would have been 87%. If a final risk score ≥26 was selected as the cut off point at which the blunt chest-wall trauma patient was considered a high enough risk to require ICU admission, then the percentage of patients correctly managed (scored at ≥26 and the observed outcome was ICU admission) was 95%. The percentage of patients who would have been incorrectly managed (scored at ≥26 but were not admitted to the ICU in the observed outcome) would have been 11%.

Discussion
==========

We have developed and validated a prognostic model for predicting the development of complications following blunt chest-wall trauma. The final model has excellent discrimination suggesting that the clinician can confidently assess whether the patient with the higher risk prediction using the model will develop complications following blunt chest-wall trauma, compared to the patients with low risk predictions who will not develop complications. As expected, the validation model demonstrated poorer calibration and numerous authors have offered explanations for this result in a validation sample \[[@B22],[@B23]\]. It is likely that the poor calibration was due to the significantly lower rates of the development of complications in the validation sample.

Common practice is simply to reject an original prediction model as a result of decreased predictive performance in the validation sample. A new prediction model is then developed and as a consequence the original dataset is neglected and clinicians are faced with numerous possible prediction models, very few of which have been externally validated for use in new samples \[[@B22]\]. Research now suggests that the model should be adjusted in order to improve its performance on the new population and this adjusted model is then based on both the original and validation data, further strengthening its stability and generalisability \[[@B9]\]. The model in this validation study was therefore updated using a previously described method known as recalibration \[[@B19],[@B23]\]. By simply adjusting the intercept for the original model, the validation model calibration was improved.

Patient age, number of rib fractures, chronic lung disease, pre-injury anticoagulants and oxygen saturation levels were the significant risk factors for development of complications following blunt chest-wall trauma. Patient age, number of rib fractures and chronic lung disease have been reported as significant risk factors for poor outcomes in a number of recent studies and possible explanations for these factors have been previously discussed \[[@B2],[@B16],[@B24]\]. Pre-injury anticoagulant use and oxygen saturation levels have only been reported as risk factors for the development for complications following blunt chest-wall trauma in a previous study by Battle *et al*. \[[@B2]\] and therefore, further research into these risk factors would be beneficial \[[@B16]\].

The results of this study have demonstrated that risk can be easily and accurately stratified from simple demographic and clinical variables on initial assessment of the blunt chest-wall trauma patient in the ED. The risk factors are all currently routinely measured in the ED and do not require expensive, time-consuming or complicated technology to investigate. This is one of the most important factors in the success of prognostic model development according to previous research \[[@B9]\]. The clinician would simply collect routine data, total the scores for each risk factor, then obtain the corresponding probability of the development of complications. A more accurate decision can be made by the clinician on whether the patient is safe for discharge home directly from the ED, or whether the patient requires admission to hospital. Not only could this reduce the development of complications in blunt chest-wall trauma patients through close observation and early aggressive prophylactic treatment in the admitted patient, but also reduce unnecessary admission of patients unlikely to develop complications.

The overall results of this study suggest that the final validation model could be safely and effectively used in the clinical setting in England and Wales for assisting in the management of blunt chest-wall trauma patients. This is the first prognostic model that has been developed and externally validated in a prospective multi-centre study for use with blunt chest-wall trauma patients. The model can be used with the less severely injured patient who on presentation to the ED is not suffering any overt signs of respiratory distress, but will potentially go on to develop severe life-threatening pulmonary complications. Research has demonstrated that careful observation and early aggressive therapy can limit these complications, therefore identification of the high-risk patient is imperative for optimal management \[[@B25]\]. It is inevitable, however, that the final decision on patient management must be individualised and many factors that cannot be translated into a statistical model must be considered. The overall purpose of the prognostic model is simply to guide clinical decision-making, not replace it.

This study has a number of strengths and limitations. External validation using a prospective multi-centre trial is considered the most robust validation technique ensuring generalisability of the study's results \[[@B9]\]. Current methodological recommendations for clinical prediction research, as outlined by Bouwmeester *et al*. \[[@B17]\] have been followed in the design and completion of the prognostic model for use with blunt chest-wall trauma patients. These recommendations included sample size and selection, clear definitions of risk factors and outcomes under investigation, handling of missing data, reporting of both univariable and multivariable results and calculation of model performance measures. The final model was also recalibrated as recommended by recent research \[[@B19]\]. As a result the reliability and applicability is sufficient that the model could be safely and effectively used in the clinical setting. The external validation results also confirm the clinical usefulness of the model in blunt chest-wall trauma management throughout England and Wales. It is important to emphasise, however, that the validation model *c*-statistic is a very unusual result and should be interpreted with caution. It is more common for the *c*-statistic to decrease in the validation study, rather than to increase as we found.

One of the limitations of this study is the loss of patients to follow up. Due to limited resources, it was not considered feasible to investigate the patients' follow up once they had left hospital care. Any use of primary care for complications that developed following hospital discharge would not have been included in the study results. The data collection was not fully blinded as recommended by Bouwmeester *et al*. \[[@B17]\], however, the clinicians collecting the data in the validation study were blinded to which of the risk factors and outcomes were being used in the final analysis. Another limitation of the validation study concerns the timing of the data collection. For example, the patient's oxygen saturation levels may have varied according to the time in which they were recorded. If the data were collected before analgesia was given in the ED, then the results may have been worse than if the patient had received analgesia and could breathe more easily. As a result of these limitations, the results of this study should be considered with caution.

There was a significantly lower rate of complications in the validation sample than the development sample. This could be explained by the protocol for management of the blunt chest-trauma patient in the different hospitals. For example, in the hospital where the original model was developed, patients are routinely admitted to the ICU if they need invasive analgesia such as an epidural, as this is where epidural patients are currently managed. In order to quantify the number of rib fractures sustained by the patient, a chest radiograph or computed tomography (CT) scan and its subjective interpretation is required. Due to the inherent difficulties in identification of rib fractures on chest radiographs, the clinician is advised to record the number of rib fractures identified on imaging, or suspected clinically following physical examination of the patient \[[@B26]\].

The use of a composite outcome measure could result in one element dominating the total outcome measure. This was not the case in this study, however, as apart from the low mortality rate, there was a relatively even number of the different types of reported complications.

Conclusions
===========

Blunt chest-wall trauma patients are often difficult to manage in the ED, due to the frequent onset of delayed complications. We have developed and validated a prognostic model, which can assist the clinician in the management of the blunt chest-wall trauma patient. The model has demonstrated excellent prediction capabilities and can be safely used in EDs managing this patient group.

Key messages
============

• Blunt chest-wall trauma patients can be difficult to manage in the ED due to the frequent onset of delayed complications

• Risk factors for the development of complications following blunt chest-wall trauma were patient age, number of rib fractures, chronic lung disease, use of pre-injury anticoagulants and oxygen saturations

• The prognostic model developed and externally validated in this study can be safely used to assist in the management of the blunt chest-wall trauma patient in the ED

• The prognostic model demonstrates excellent predictive capabilities
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CT: computed tomography; ED: emergency department.
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